CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
CERo Therapeutics Holdings (NASDAQ: CERO) announces significant expansion of its intellectual property portfolio with two new patent application allowances from the USPTO for its lead compound CER-1236.
The first patent (No. 17/040,472) covers composition and methods for combining phosphatidylserine-targeting CD4+ CER-T cells with CD8+ CAR-T or TCR-T cells for cancer treatment. The second patent (No. 17/040,317) protects design aspects of CER-1236, specifically the chimeric TIM4 receptor composition.
The company's IP portfolio now comprises 9 patent families with US protection until 2039 and 17 total issued and allowed patents internationally. These developments coincide with CERo's progress in Phase 1 trials for AML treatment and recently cleared IND for ovarian and non-small cell lung cancer trials.
CERo Therapeutics Holdings (NASDAQ: CERO) annuncia un'espansione significativa del proprio portafoglio di proprietà intellettuale con due nuove concessioni di domanda di brevetto da parte dell'USPTO per il suo composto principale CER-1236.
Il primo brevetto (No. 17/040,472) copre composizioni e metodi per combinare cellule CER-T CD4+ mirate alla fosfatidilserina con cellule CAR-T o TCR-T CD8+ per il trattamento del cancro. Il secondo brevetto (No. 17/040,317) protegge aspetti di design di CER-1236, in particolare la composizione del recettore chimerico TIM4.
Il portafoglio di proprietà intellettuale dell'azienda ora comprende 9 famiglie di brevetti con protezione negli Stati Uniti fino al 2039 e 17 brevetti totali emessi e concessi a livello internazionale. Questi sviluppi coincidono con i progressi di CERo nei trial di Fase 1 per il trattamento dell'AML e con l'IND recentemente approvato per i trial sui tumori ovarici e sul cancro del polmone non a piccole cellule.
CERo Therapeutics Holdings (NASDAQ: CERO) anuncia una expansión significativa de su cartera de propiedad intelectual con dos nuevas concesiones de solicitudes de patente por parte de la USPTO para su compuesto principal CER-1236.
La primera patente (No. 17/040,472) cubre composiciones y métodos para combinar células CER-T CD4+ dirigidas a la fosfatidilserina con células CAR-T o TCR-T CD8+ para el tratamiento del cáncer. La segunda patente (No. 17/040,317) protege aspectos de diseño de CER-1236, específicamente la composición del receptor quimérico TIM4.
El portafolio de propiedad intelectual de la empresa ahora comprende 9 familias de patentes con protección en EE. UU. hasta 2039 y 17 patentes totales emitidas y concedidas internacionalmente. Estos desarrollos coinciden con el progreso de CERo en los ensayos de Fase 1 para el tratamiento de la AML y la aprobación reciente de IND para ensayos de cáncer de ovario y cáncer de pulmón no microcítico.
CERo Therapeutics Holdings (NASDAQ: CERO)는 주력 화합물 CER-1236에 대해 USPTO로부터 두 개의 새로운 특허 신청 허가를 받아 지적 재산 포트폴리오를 대폭 확장했다고 발표했습니다.
첫 번째 특허(번호 17/040,472)는 암 치료를 위해 인지질세린 표적 CD4+ CER-T 세포와 CD8+ CAR-T 또는 TCR-T 세포를 결합하는 조성물 및 방법을 포함합니다. 두 번째 특허(번호 17/040,317)는 CER-1236의 디자인 측면을 보호하며, 특히 키메라 TIM4 수용체 조성을 다룹니다.
회사의 지적 재산 포트폴리오는 이제 9개의 특허 패밀리로 구성되어 있으며, 미국에서 2039년까지 보호받고 국제적으로 총 17개의 발급 및 허가된 특허를 보유하고 있습니다. 이러한 발전은 AML 치료를 위한 1상 시험에서 CERo의 진행 상황과 최근에 승인된 난소암 및 비소세포 폐암 시험을 동반합니다.
CERo Therapeutics Holdings (NASDAQ: CERO) annonce une expansion significative de son portefeuille de propriété intellectuelle avec deux nouvelles demandes de brevet acceptées par l'USPTO pour son composé principal CER-1236.
Le premier brevet (No. 17/040,472) couvre des compositions et des méthodes pour combiner des cellules CER-T CD4+ ciblant la phosphatidylsérine avec des cellules CAR-T ou TCR-T CD8+ pour le traitement du cancer. Le deuxième brevet (No. 17/040,317) protège des aspects de conception de CER-1236, notamment la composition du récepteur chimérique TIM4.
Le portefeuille de propriété intellectuelle de l'entreprise comprend désormais 9 familles de brevets avec une protection aux États-Unis jusqu'en 2039 et 17 brevets au total délivrés et accordés à l'international. Ces développements coïncident avec les progrès de CERo dans les essais de Phase 1 pour le traitement de l'AML et l'IND récemment approuvé pour les essais sur le cancer de l'ovaire et le cancer du poumon non à petites cellules.
CERo Therapeutics Holdings (NASDAQ: CERO) gibt eine bedeutende Erweiterung seines Portfolios an geistigem Eigentum mit zwei neuen Patentanmeldungen bekannt, die von der USPTO für seinen Hauptbestandteil CER-1236 genehmigt wurden.
Das erste Patent (Nr. 17/040,472) umfasst Zusammensetzungen und Methoden zur Kombination von phosphatidylserin-zielgerichteten CD4+ CER-T-Zellen mit CD8+ CAR-T- oder TCR-T-Zellen zur Krebsbehandlung. Das zweite Patent (Nr. 17/040,317) schützt Gestaltungsaspekte von CER-1236, insbesondere die Zusammensetzung des chimären TIM4-Rezeptors.
Das IP-Portfolio des Unternehmens umfasst nun 9 Patentfamilien mit US-Schutz bis 2039 und insgesamt 17 international erteilte und genehmigte Patente. Diese Entwicklungen fallen mit den Fortschritten von CERo in den Phase-1-Studien zur Behandlung von AML und der kürzlich genehmigten IND für Studien zu Eierstock- und nicht-kleinzelligem Lungenkrebs zusammen.
- Secured two new strategic patent allowances for lead compound CER-1236
- Extended patent protection until 2039 in the US
- Expanded intellectual property portfolio to 17 total issued/allowed patents internationally
- Advanced to Phase 1 trials for multiple cancer indications
- None.
Insights
These patent allowances represent a significant strengthening of CERo's intellectual property foundation for their lead compound CER-1236. The most valuable aspect is that these patents provide composition of matter protection - the strongest form of patent protection in pharmaceuticals - rather than just method patents.
The first allowed patent covers the combination of phosphatidylserine-targeting CD4+ CER-T cells with CD8+ CAR-T or TCR-T cells for cancer treatment, while the second protects the chimeric TIM4 receptor design fundamental to their technology. With protection extending to 2039, CERo has secured market exclusivity through what would be the most commercially valuable years should their therapy advance to approval.
CERo's expansion to 17 total patents across 9 patent families demonstrates a sophisticated multi-layered IP strategy essential in the competitive cellular therapy space. This comprehensive protection creates significant barriers to competitors attempting to develop similar phagocytic mechanism-based T cell therapies.
The timing aligns strategically with their clinical progress into Phase 1 trials for AML, ovarian, and non-small cell lung cancers. For an early-stage biotech with a
Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families
SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the allowance of two patent applications submitted to the U.S. Patent and Trademark Office (USPTO), which materially expands the Company’s intellectual property portfolio.
Patent Application No. 17/040,472, titled, “CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,” was allowed on March 13, 2025 and provides coverage for composition of matter and methods of use coverage for the Company’s lead compound, CER-1236. The allowed claims encompass the combination of a phosphatidylserine-targeting CD4+ CER-T cell with a CD8+ CAR-T cell or a CD8+ recombinant TCR-T cell, and their use to treat cancer. This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
Additionally, the USPTO has issued a Notice of Allowance on March 24, 2025 for Patent Application No. 17/040,317, titled, “CHIMERIC TIM4 RECEPTORS AND USES THEREOF.” The allowed claims encompass some design aspects of CER-1236. This patent, once granted, provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains. CERo’s intellectual property portfolio now includes 9 total patent families with protection out to 2039 in the United States. With these additional allowed applications, CER-1236 and its platform technology is supported by 17 total issued patents and allowed patent applications internationally.
Chris Ehrlich, CERo Therapeutics CEO, commented, “These additional patent application allowances are paramount to CERo’s success in the market as they demonstrate the true novelty of our design and approach in potentially killing cancer cells and treating patients. The robust range of patents that cover this technology in general, and CER-1236 in particular, are a continuation of the validation we have seen since the inception of the Company, demonstrating innovation -- and we believe – therapeutic potential. We are gratified to be receiving these allowances on the heels of the announcement of our initial trial site for our Phase 1 trial in AML and the announcement of our cleared IND to begin human trials to treat ovarian and non-small cell lung cancers.”
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo and the implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
FAQ
What new patent allowances did CERo Therapeutics (CERO) receive for CER-1236?
How long does CERo's (CERO) patent protection extend in the United States?
What cancers is CERo Therapeutics (CERO) targeting with CER-1236 in clinical trials?
How many total patents and patent families does CERo (CERO) now have?
